Management of Ovarian Cancer and Soft Tissue Sarcoma: Focus on Trabectedin
نویسندگان
چکیده
Ovarian cancer (OVCA) and soft tissue sarcoma (STS) are cancers that cause low survival rates when diagnosed at advanced disease stage and patients with these cancers usually suffer from recurrent disease. Trabectedin, an alkaloid of marine origin has recently demonstrated improvement in managing advanced recurrent OVCA and STS. It is currently approved as a single therapeutic agent for second line therapy of STS in the USA and Europe. It is also approved in combination with pegylated liposomal doxorubicin as a second line therapy for OVCA in Europe. This review summarizes recent clinical data demonstrating the efficacy of using trabectedin as a second line therapy in OVCA and in STS.
منابع مشابه
New developments in treatment of ovarian carcinoma: focus on trabectedin
Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA repair machinery. Trabectedin has shown promising single-agent activity in pretreated patients with soft tissue sarcoma, and ovarian and breast cancer, and combination with various other chemotherapeutic drugs seems feasible. Toxicities are mainly hematologic and hepatic, with Gra...
متن کاملClinical utility of trabectedin for the treatment of ovarian cancer: current evidence
Among the pharmaceutical options available for treatment of ovarian cancer, attention has been increasingly focused on trabectedin (ET-743), a drug which displays a unique mechanism of action and has been shown to be active in several human malignancies. Currently, single agent trabectedin is approved for treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines an...
متن کاملAdvanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxici...
متن کاملCEV_5993_Trabectedin the evidence for its place in therapy
Correspondence: Katherine A Thornton Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University, Baltimore, MD, USA Email [email protected] Introduction: Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing new therapeutics has ...
متن کاملTrabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma
INTRODUCTION Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing new therapeutics has been difficult, at best. The standard of care in the treatment of advanced and metastatic disease over the last 30 years has been doxorubicin and ifosfamide...
متن کامل